Detalles de la búsqueda
1.
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
Br J Dermatol
; 180(5): 1039-1049, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30485400
2.
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
Br J Dermatol
; 178(1): 114-123, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28635018
3.
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
Br J Dermatol
; 178(1): 132-139, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28940259
4.
Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
J Eur Acad Dermatol Venereol
; 32(9): 1515-1522, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29512196
5.
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
J Eur Acad Dermatol Venereol
; 32(11): 1940-1949, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29706008
6.
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.
Br J Dermatol
; 172(5): 1371-83, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25307931
7.
Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
Br J Dermatol
; 170(2): 398-407, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24117389
8.
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
Br J Dermatol
; 168(4): 844-54, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23301632
9.
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
J Eur Acad Dermatol Venereol
; 27(12): 1535-45, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23279003
10.
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
Br J Dermatol
; 167(5): 1145-52, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22803615
11.
The presence of hospitalists in medical education.
Acad Med
; 75(10 Suppl): S34-6, 2000 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-11031167
12.
Fas promoter polymorphisms: genetic predisposition to sarcoidosis in African-Americans.
Tissue Antigens
; 72(1): 39-48, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18588573
Resultados
1 -
12
de 12
1
Próxima >
>>